Evaluation of RC28-E Injection in Diabetic Retinopathy

A Randomized, Open-label, Multicenter Study of the Efficacy and Safety of RC28-E Injection in Subjects With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy

This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy.

Study Overview

• Status: Active, not recruiting
• Conditions: Diabetic Retinopathy
• Intervention / Treatment: Biological: RC28-E injection

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100730
      • Beijing Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Sign the consent form, willing and able to comply with clinic visits and study-related procedures;
• Aged 18 years to 80 years, male or female;
• Diabetes mellitus(type 1 or 2);
• Moderately severe to severe NPDR (DRSS levels 47 or 53) which was confirmed by the central reading center, and in whom PRP can be safely deferred by the investigator's judgement;
• BCVA score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better) using the ETDRS protocol at an initial testing distance of 4 meters;
• If both eyes meet the inclusion criterion, one eye with poor BCVA is selected as the study eye;

Exclusion Criteria:

• Presence of DME threatening the center of the macula (within 1,000 microns of the foveal center) in the study eye;
• Evidence of retinal neovascularization on clinical examination or FA;
• Any prior focal or grid laser photocoagulation (within 1,000 microns of the foveal center) or PRP in the study eye;
• Current ASNV, vitreous hemorrhage, tractional retinal detachment or epiretinal membrane involved the macular in the study eye;
• History of vitreoretinal surgery in the study eye;
• Active infectious blepharitis, keratitis, scleritis, conjunctivitis at the screening assessments in either eye ;
• Previous treatment with anti-angiogenic drugs in either eye or system (ranibizumab, aflibercept, conbercept, etc) within 3 months of the Day 0 visit;
• Previous use of intraocular or periocular corticosteroids (such as triamcinolone acetonide, dexamethasone vitreous implant) in either eye within 6 months of day 0.
• Uncontrolled clinical disease (such as severe psychiatric, neurological, cardiovascular, respiratory disease or other systemic diseases) and tumors;
• Pregnant or lactating women, subjects who had family planning throughout the study period;
• Those who participated in clinical trials for 3 months or 5 half-lives of the investigational product (the longer the time) before theDay 0
• Those who considered unsuitable for enrollment by investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: intravitreal 1.0mg RC28-E injection Q8; Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.	Biological: RC28-E injection; a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
Experimental: Experimental: intravitreal 1.0mg RC28-E injection PRN; Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.	Biological: RC28-E injection; a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
Experimental: Experimental: intravitreal 2.0mg RC28-E injection Q8; Subjects received 2.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.	Biological: RC28-E injection; a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
Experimental: Experimental: intravitreal 2.0mg RC28-E injection PRN; Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.	Biological: RC28-E injection; a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The proportion of subjects who have improved by ≥2 steps from baseline in DRSS score at week 24, 52	The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24, 52 from baseline	At Week 24, 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 24, 52	Vision-threatening complications are defined as the composite outcome of proliferative diabetic retinopathy (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris and/or definitive neovascularization of the iridocorneal angle).	At Week 24, 52
Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 24, 52;	The percentage of participants who developed CI-DME at week24, 52 were reported.	At Week 24, 52
Mean Change from Baseline in Best Corrected Visual Acuity (BCVA);	Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.	Baseline up to week 52
Mean change from baseline in DRSS score;	The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24, 52 from baseline.	Baseline upto week 52
Percentage of Participants Who Received Panretinal Photocoagulation (PRP) at Week24, 52;	The percentage of participants who received panretinal photocoagulation (PRP).	At Week 24, 52
Percentage of participants who undergoing Vitrectomy at Week24, 52;	The percentage of participants who undergoing vitrectomy.	At Week 24, 52
Frequency of administration RC28-E;	Number of intravitreal injections	At Week 24, 52
Safety of RC28-E injection	Incidence of AE in ocular and non-ocular	Baseline upto week 52

Collaborators and Investigators

• Sponsor: RemeGen Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): May 25, 2021
• Primary Completion (Estimated): May 1, 2024
• Study Completion (Estimated): July 1, 2024

Study Registration Dates

• First Submitted: March 1, 2021
• First Submitted That Met QC Criteria: March 1, 2021
• First Posted (Actual): March 4, 2021

Study Record Updates

• Last Update Posted (Actual): October 11, 2023
• Last Update Submitted That Met QC Criteria: October 10, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Eye Diseases; Endocrine System Diseases; Diabetic Angiopathies; Diabetes Complications; Diabetes Mellitus; Retinal Diseases; Diabetic Retinopathy; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; RC28-E protein
• Other Study ID Numbers: 28C003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No